These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

308 related articles for article (PubMed ID: 19366571)

  • 61. Effect of common protective antigen vaccination to protect mink from challenge exposure with Pseudomonas aeruginosa.
    Shimizu T; Homma JY; Abe C; Tanamoto T; Aoyama Y; Yanagawa R; Fujimoto Y; Noda H; Takashima I; Honda E; Minamide S
    Am J Vet Res; 1976 Dec; 37(12):1441-4. PubMed ID: 826199
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Killed but metabolically active Pseudomonas aeruginosa-based vaccine induces protective humoral- and cell-mediated immunity against Pseudomonas aeruginosa pulmonary infections.
    Meynet E; Laurin D; Lenormand JL; Camara B; Toussaint B; Le Gouëllec A
    Vaccine; 2018 Mar; 36(14):1893-1900. PubMed ID: 29506924
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Synthetic peptide vaccine and antibody therapeutic development: prevention and treatment of Pseudomonas aeruginosa.
    Cachia PJ; Hodges RS
    Biopolymers; 2003; 71(2):141-68. PubMed ID: 12767116
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Determination of IgG subclass antibodies to Pseudomonas aeruginosa outer membrane proteins in cystic fibrosis lung infection using immunoblotting and enzyme-linked immunosorbent assay.
    Pressler T; Kronborg G; Shand GH; Mansa B; Høiby N
    Med Microbiol Immunol; 1992; 181(6):339-49. PubMed ID: 1287420
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Phase I study of a candidate vaccine based on recombinant HIV-1 gp160 (MN/LAI) administered by the mucosal route to HIV-seronegative volunteers: the ANRS VAC14 study.
    Pialoux G; Hocini H; Pérusat S; Silberman B; Salmon-Ceron D; Slama L; Journot V; Mathieu E; Gaillard C; Petitprez K; Launay O; Chêne G;
    Vaccine; 2008 May; 26(21):2657-66. PubMed ID: 18068876
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Specific IgA against
    Millares L; Martí S; Ardanuy C; Liñares J; Santos S; Dorca J; García-Nuñez M; Quero S; Monsó E
    Int J Chron Obstruct Pulmon Dis; 2017; 12():2807-2811. PubMed ID: 29033561
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Autoantibody response to BPI predict disease severity and outcome in cystic fibrosis.
    Carlsson M; Eriksson L; Pressler T; Kornfält R; Mared L; Meyer P; Wiik A; Wieslander J; Segelmark M
    J Cyst Fibros; 2007 May; 6(3):228-33. PubMed ID: 17166780
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Local application of CpG oligodeoxynucleotide enhances nontypeable Haemophilus influenzae-specific mucosal IgA responses in the middle ear.
    Kodama S; Hirano T; Abe N; Suzuki M
    Acta Otolaryngol; 2007 Aug; 127(8):809-15. PubMed ID: 17762989
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Antibody response against Pseudomonas aeruginosa and its relationship with immune mediators in the upper and lower airways of cystic fibrosis patients.
    Mauch RM; Hentschel J; Aanaes K; Barucha A; Nolasco da Silva MT; Levy CE; Høiby N; Mainz JG
    Pediatr Pulmonol; 2020 Apr; 55(4):959-967. PubMed ID: 32022432
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Mucosal and systemic immunization with targeted fusion anti-caries DNA plasmid in young rats.
    Liu GX; Xu QA; Jin J; Li YH; Jia R; Guo JH; Fan MW
    Vaccine; 2009 May; 27(22):2940-7. PubMed ID: 19428904
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Secretory IgA-mediated immune response in saliva and early detection of Pseudomonas aeruginosa in the lower airways of pediatric cystic fibrosis patients.
    Mauch RM; Rossi CL; Nolasco da Silva MT; Bianchi Aiello T; Ribeiro JD; Ribeiro AF; Høiby N; Levy CE
    Med Microbiol Immunol; 2019 Apr; 208(2):205-213. PubMed ID: 30706137
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Immunization with Pseudomonas aeruginosa outer membrane vesicles stimulates protective immunity in mice.
    Zhang X; Yang F; Zou J; Wu W; Jing H; Gou Q; Li H; Gu J; Zou Q; Zhang J
    Vaccine; 2018 Feb; 36(8):1047-1054. PubMed ID: 29406241
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Defining the Mechanistic Correlates of Protection Conferred by Whole-Cell Vaccination against Pseudomonas aeruginosa Acute Murine Pneumonia.
    Sen-Kilic E; Blackwood CB; Huckaby AB; Horspool AM; Weaver KL; Malkowski AC; Witt WT; Bevere JR; Damron FH; Barbier M
    Infect Immun; 2021 Jan; 89(2):. PubMed ID: 33199354
    [No Abstract]   [Full Text] [Related]  

  • 74. A controlled clinical trial of a therapeutic bacteriophage preparation in chronic otitis due to antibiotic-resistant Pseudomonas aeruginosa; a preliminary report of efficacy.
    Wright A; Hawkins CH; Anggård EE; Harper DR
    Clin Otolaryngol; 2009 Aug; 34(4):349-57. PubMed ID: 19673983
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Variable antibiotic susceptibility in populations of Pseudomonas aeruginosa infecting patients with bronchiectasis.
    Gillham MI; Sundaram S; Laughton CR; Haworth CS; Bilton D; Foweraker JE
    J Antimicrob Chemother; 2009 Apr; 63(4):728-32. PubMed ID: 19193658
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Mucosal vaccination approach against mosquito-borne Japanese encephalitis virus.
    Harakuni T; Kohama H; Tadano M; Uechi G; Tsuji N; Matsumoto Y; Miyata T; Tsuboi T; Oku H; Arakawa T
    Jpn J Infect Dis; 2009 Jan; 62(1):37-45. PubMed ID: 19168957
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Protection against hemorrhagic pneumonia of mink by Pseudomonas aeruginosa multicomponent vaccine.
    Aoi Y; Noda H; Yanagawa R; Homma JY; Abe C; Morihara K; Goda A; Takeuchi S; Ishihara T
    Jpn J Exp Med; 1979 Jun; 49(3):199-207. PubMed ID: 114699
    [TBL] [Abstract][Full Text] [Related]  

  • 78. In vivo induction of mucosal immune responses by intranasal administration of chitosan microspheres containing Bordetella bronchiseptica DNT.
    Kang ML; Kang SG; Jiang HL; Shin SW; Lee DY; Ahn JM; Rayamahji N; Park IK; Shin SJ; Cho CS; Yoo HS
    Eur J Pharm Biopharm; 2006 Jun; 63(2):215-20. PubMed ID: 16531027
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Prophylaxis and therapy of Pseudomonas aeruginosa infection in cystic fibrosis and immunocompromised patients.
    Lang AB; Horn MP; Imboden MA; Zuercher AW
    Vaccine; 2004 Dec; 22 Suppl 1():S44-8. PubMed ID: 15576201
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Th17-stimulating protein vaccines confer protection against Pseudomonas aeruginosa pneumonia.
    Wu W; Huang J; Duan B; Traficante DC; Hong H; Risech M; Lory S; Priebe GP
    Am J Respir Crit Care Med; 2012 Sep; 186(5):420-7. PubMed ID: 22723292
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.